Vectura wins additional $10m patent damages against GSK
A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline ( GSK) has willfully infringed one of its patents.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 November 2020 The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.
8 October 2019 The English High Court has sided with pharmaceutical company Vectura and Novartis-owned Sandoz in a passing off lawsuit brought by rival GSK.
7 May 2019 British drugmaker Vectura has succeeded in its patent litigation against fellow UK pharmaceutical company GlaxoSmithKline over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.
